Cardinal Health announced an exclusive multi-year U.S. agreement with T2 Biosystems to distribute its FDA-cleared direct-from-blood diagnostics for rapid detection of sepsis-causing pathogens. This partnership includes the T2Dx Instrument, the T2Bacteria Panel, and the T2Candida Panel.
The collaboration is expected to significantly expand Cardinal Health's access to the U.S. hospital market, leveraging its extensive commercial and distribution infrastructure. Sepsis remains a leading cause of death and hospitalization costs in the U.S., highlighting the demand for advanced diagnostic technologies.
T2 Biosystems' technology offers rapid detection in 3-5 hours, without waiting days for blood culture results, and is not affected by prior antimicrobial treatment. This agreement positions Cardinal Health to offer innovative solutions that strengthen sepsis clinical care and improve patient outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.